a model including cd49d expression to predict outcomes in patients with cll treated with ibrutinib
Published 1 month ago • 22 plays • Length 2:55Download video MP4
Download video MP3
Similar videos
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
0:59
hdxsim: a clinical decision support tool for model-informed precision dosing of hydroxyurea in scd
-
3:03
the evolution of treatment patterns and prognostic biomarkers in latin american cll patients
-
3:59
using enhanced ctdna profiling to identify molecular determinants of response in r/r mcl
-
2:29
the measurement of molecular biomarkers to aid cll treatment
-
3:18
a phase i study of jbh492, an anti-ccr7 antibody-drug conjugate, in lymphoid malignancies
-
21:38
drawing the line: the rationale behind blood tube collection order
-
1:46:07
hematology lecture
-
5:22
magrolimab azacitidine in mds and aml
-
4:25
cll: state of the art in italy
-
2:29
the role of the multidisciplinary team in providing adequate diagnosis & treatment for bpdcn
-
2:41
an overview of the latest advances in hematology
-
2:07
phase i/ii study of edit-301, a novel gene-edited autologous hsc medicine, in patients with scd
-
1:31
pembrolizumab plus avd in chl: long-term follow-up of a phase ii study
-
0:47
overview of the phase iii enhance trial schema
-
3:10
the potential for early identification of relapse in dlbcl using serial ctdna sampling
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
4:15
diagnostic tools for wm and the importance of whole genome sequencing
-
1:52
exploring the possibility of treating scd in-utero with novel gene-editing technology
-
8:57
outcomes of sct in t-all and t-lbl
-
1:18
the importance of lymphodepletion, an undervalued component of the car-t therapy cycle